Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer. We present final overall survival (OS) results (n = 88) from a randomized phase 2 trial of eribulin ± pembrolizumab for patients with metastatic HR+ breast cancer, computationally d...

Descripción completa

Detalles Bibliográficos
Autores principales: Keenan, Tanya E., Guerriero, Jennifer L., Barroso-Sousa, Romualdo, Li, Tianyu, O’Meara, Tess, Giobbie-Hurder, Anita, Tayob, Nabihah, Hu, Jiani, Severgnini, Mariano, Agudo, Judith, Vaz-Luis, Ines, Anderson, Leilani, Attaya, Victoria, Park, Jihye, Conway, Jake, He, Meng Xiao, Reardon, Brendan, Shannon, Erin, Wulf, Gerburg, Spring, Laura M., Jeselsohn, Rinath, Krop, Ian, Lin, Nancy U., Partridge, Ann, Winer, Eric P., Mittendorf, Elizabeth A., Liu, David, Van Allen, Eliezer M., Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455578/
https://www.ncbi.nlm.nih.gov/pubmed/34548479
http://dx.doi.org/10.1038/s41467-021-25769-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455578/
https://www.ncbi.nlm.nih.gov/pubmed/34548479
http://dx.doi.org/10.1038/s41467-021-25769-z

Ejemplares similares